Annual sales were KRW 21.1 billion in 2023, KRW 14.8 billion in 2024 (down 29.5% year on year) and KRW 53.4 billion in 2025 (up 259.8% year on year), making 2025 the largest year and 2024 the smallest within 2023-2025.
Operating profit went from KRW 2.23 billion in 2023 to an operating loss of KRW 4.8 billion in 2024, a swing to a loss, before returning to operating profit of KRW 12.6 billion in 2025. The operating margin was 10.6% in 2023, -32.3% in 2024 and 23.6% in 2025.
Profit attributable to controlling shareholders was KRW 1.68 billion in 2023, a loss of KRW 8.09 billion in 2024 (a swing to a loss), and KRW 15.8 billion in 2025. Net profit including non-controlling interests was reported as KRW 1.68 billion, a net loss of KRW 8.09 billion and KRW 15.8 billion in the same years.
At the end of 2025, total equity was KRW 72 billion, all of it attributable to controlling shareholders, total liabilities were KRW 3.67 billion, and the debt ratio was 5.1%. Operating cash flow was KRW 4.15 billion in 2023, -KRW 7.84 billion in 2024 and KRW 11.4 billion in 2025.
On a quarterly basis, sales of KRW 19.2 billion and operating profit of KRW 8.32 billion in the third quarter of 2025 were followed by sales of KRW 15.6 billion (down 18.9% from the prior quarter) and operating profit of KRW 1.61 billion in the fourth quarter.
Sales rebounded to KRW 23 billion in the first quarter of 2026 (up 47.5% from the prior quarter) with operating profit of KRW 4.59 billion. In the second quarter of 2026, sales were KRW 24.4 billion and operating profit KRW 2.79 billion.
Third-quarter 2026 sales were KRW 17 billion (down 11.4% year on year), with an operating loss of KRW 4.35 billion, a swing from profit a year earlier.
The company attributed the sales decline to lower production during summer holidays and the operating loss to higher R&D spending from new pipeline research and expanded clinical trials at home and abroad.
According to BusinessWatch, cumulative R&D spending for the first three quarters of 2026 was KRW 20.7 billion, about 3.4 times the KRW 6.1 billion a year earlier, and the R&D-to-sales ratio rose from 16% to 32%.
The third-quarter loss attributable to controlling shareholders of KRW 7.69 billion was larger than the operating loss, which press reports tie to a foreign currency translation loss on dollar-denominated assets.
The company's investor materials say a Chinese partner's milestone was booked in the first quarter of 2025, so annual results include one-time contract income. Profit trends depend on whether Jacubo's prescription growth can absorb the expansion in R&D, and they should be read alongside the quarterly pattern.